What are the necessary precautions when administering subcutaneous (SQ) immunotherapy?

Subcutaneous immunotherapy (SQIT) involves the administration of allergens in a controlled manner to develop tolerance in patients with allergic conditions. Administering this therapy requires close monitoring due to the risk of adverse reactions, particularly anaphylaxis, which can occur shortly after administration.

The necessity for supervision in a healthcare setting emphasizes patient safety. This monitoring is crucial during and after the administration of each dose, particularly the initial doses when the risk of serious allergic reactions is higher. Medical professionals have the training and tools necessary to manage any potential adverse reactions promptly, ensuring the safety of the patient.

Therefore, administering SQ immunotherapy in a doctor's office allows for immediate intervention if a severe allergic reaction occurs, making it the standard practice in immunotherapy care. This highlights the importance of administering this treatment under supervision rather than at home, where resources to manage emergencies may not be readily available.